Acrux Limited (FRA:FJY)

Germany · Delayed Price · Currency is EUR

0.0010

0.00 (0.00%)

Last updated: Aug 27, 2026, 8:05 AM CET

-71.43% (1Y)

Market Cap	3.61M +14.3%
Revenue (ttm)	3.99M +45.7%
Net Income	-365.74K
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0010
Previous Close	0.0010
Day's Range	0.0010 - 0.0010
52-Week Range	0.0005 - 0.0190
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About Acrux

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for the treatment of acne vulgaris; and Lidocaine and Prilocaine Cream USP, a topical anesthetic cream. It is also involved in the development of Efinaconazo... [Read more]

Industry Pharmaceutical Preparations

Founded 1998

Employees 43

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol FJY

Financial Performance

In fiscal year 2026, Acrux's revenue was 6.60 million, an increase of 454.29% compared to the previous year's 1.19 million. Losses were -604,000, -89.84% less than in 2025.

Financial numbers in AUD Financial Statements